|
T9962 |
Mepolizumab
|
SB 240563 |
IL Receptor
|
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody neutralizing IL-5. Mepolizumab can be used in studies about severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. |
|
T10497 |
Benralizumab
|
BIW-8405,MEDI-563 |
Apoptosis
,
IL Receptor
,
Interleukin
|
|
|
|
TP2008L |
Lyn peptide inhibitor acetate
|
Lyn peptide inhibitor acetate(222018-18-0 free base) |
IL Receptor
|
|
Lyn peptide inhibitor acetate is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor blocks Lyn activation and inhibits the bind... |
|
T12706 |
Reslizumab
|
Sch 55700 |
IL Receptor
|
|
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. |
|
T30535 |
BMS-639623
|
UNII-PON9OFP69G,PON9OFP69G,BMS 639623,CHEMBL399495 |
|
|
BMS-639623 is a CCR3 antagonist with a picomolar inhibitory effect on eosinophilic chemotaxis and can be used in the treatment of asthma. |
|
T11521 |
GW 766994
|
GW 994 |
CCR
|
|
|
|
TP2008 |
Lyn peptide inhibitor
|
|
|
|
Cell-permeable inhibitor of Lyn-dependent effects of the IL-5 receptor. Blocks binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors, blocking Lyn activation. Inhibits IL-5 receptor-mediated eosinoph... |
|
T75806 |
Lyn peptide inhibitor TFA
|
|
|
|
Lyn Peptide Inhibitor TFA is a powerful, cell-permeable inhibitor specifically targeting the Lyn-coupled IL-5 receptor signaling pathway, without affecting alternative signaling pathways. It effectively prevents Lyn acti... |
|
T76942 |
Cendakimab
|
|
|
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective humanized recombinant monoclonal antibody targeting the IL-13 molecule with high specificity. It demonstrates potent affinity for both the wild-type and variant form... |
